IND content of a previously cleared pulmonary device

A drug manufacturer sought Chimera’s advice on device content for an IND-eCTD to support clinical development of a pulmonary drug using a delivery system which was previously pre-market cleared for general use. Chimera provided the Sponsor with advice on IND content, including device biocompatibility, compatibility and performance data, with the investigational drug.